Emerging preclinical and clinical evidence indicates that the UGT pathway differs between cancer and normal cells, with alteration in acute and chronic leukaemias, as well as in several solid tumours, affecting disease progression and patient outcomes. Here, SLC35A2 is linked to cancer.